Praxis Precision Medicines, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company that translates genetic insights from epilepsies into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance; it employs proprietary small molecule platform Cerebrum and antisense oligonucleotide (ASO) platform Solidus to develop treatments targeting shared biological mechanisms in epilepsy, movement disorders, and related conditions. The company offers a pipeline including ulixacaltamide (PRAX-944), a selective T-type calcium channel inhibitor in Phase 3 for essential tremor; relutrigine (PRAX-562), a sodium channel blocker in Phase 2/3 for SCN2A/SCN8A developmental and epileptic encephalopathies (DEEs) and gaining Rare Pediatric Disease Designation for Dravet syndrome; vormatrigine (PRAX-628), a voltage-gated sodium channel modulator in Phase 2/3 for focal epilepsy, idiopathic generalized epilepsy, and expanding to pain indications with topline data expected in 2025-2026; elsunersen, an ASO targeting Nav1.2 in Phase 1/2 for precocious puberty and SCN2A-DEE; and preclinical programs such as SYNGAP1-targeted therapies for epilepsy. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis Precision Medicines operates primarily in the United States with global clinical trial reach and maintains license agreements with RogCon Inc. and a research collaboration with Ionis Pharmaceuticals, Inc. Recent developments include a $567 million public offering in 2025 to fund operations into 2028 and advance relutrigine and vormatrigine; completion of recruitment for the POWER1 study of vormatrigine in focal onset seizures with results anticipated in first-half 2026; initiation of the POWER2 study; positive interim data from EMBOLD for relutrigine in DEEs prompting Cohort 2 recruitment and progression to registrational stages; and an October 2025 public offering priced at approximately $956 million pro forma cash position.
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
Praxis Precision Medicines Provides Vormatrigine Program Update
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Buy” by Brokerages
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor